Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas toolCopy Portfolios

Atossa on go with mid-stage study of Endoxifen in Sweden; shares up 13% premarket

Published 04/30/2018, 09:20 AM
© Reuters. Atossa on go with mid-stage study of Endoxifen in Sweden; shares up 13% premarket
ATOS
-
  • Atossa Genetics (NASDAQ:ATOS) is up 13% premarket on modest volume on the heels of its announcement that the Swedish Medical Products Agency has signed off on a Phase 2 clinical trial assessing topical Endoxifen in women with mammographic breast density (MBD).
  • The primary endpoint of the 90-subject study will be the change in MBD at month 3 and month 6 compared to placebo.
  • The company says studies have shown that reducing MBD reduces the risk of developing breast cancer and may improve the accuracy of mammography in finding cancer.
  • Endoxifen is an active metabolite of tamoxifen, the active ingredient in AstraZeneca's Nolvadex (the company stopped making it in June 2006).
  • Previously: Atossa's endoxifen shows much quicker absorption than tamoxifen in early-stage study; shares up 10% after hours (Feb. 1)
  • Now read: Your Daily Pharma Scoop: Alder's Migraine Data, Centene Revenues, Tesaro's Positive Results


Original article

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.